Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

According to Zacks, “Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company’s lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada. “

Other analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, October 23rd. Seaport Global Securities reissued a “buy” rating and issued a $10.00 price target on shares of Aurinia Pharmaceuticals in a report on Friday, October 6th. Canaccord Genuity set a $11.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, November 17th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, November 15th. Finally, Vetr downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.72 price target on the stock. in a report on Monday, August 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Aurinia Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $10.79.

Aurinia Pharmaceuticals (NASDAQ AUPH) traded down $0.30 during midday trading on Wednesday, hitting $4.70. 1,730,995 shares of the stock traded hands, compared to its average volume of 3,641,973. Aurinia Pharmaceuticals has a 12-month low of $2.02 and a 12-month high of $10.54.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The company’s revenue for the quarter was up .0% on a year-over-year basis. research analysts expect that Aurinia Pharmaceuticals will post -1.05 earnings per share for the current year.

Several large investors have recently modified their holdings of AUPH. Morgan Stanley boosted its holdings in shares of Aurinia Pharmaceuticals by 11,061.7% in the 1st quarter. Morgan Stanley now owns 446,135 shares of the biotechnology company’s stock worth $3,273,000 after buying an additional 442,138 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $776,000. Vivo Capital LLC lifted its holdings in Aurinia Pharmaceuticals by 68.9% during the second quarter. Vivo Capital LLC now owns 1,013,149 shares of the biotechnology company’s stock valued at $6,211,000 after purchasing an additional 413,149 shares during the last quarter. Alps Advisors Inc. purchased a new stake in Aurinia Pharmaceuticals during the second quarter valued at about $454,000. Finally, Bank of New York Mellon Corp lifted its holdings in Aurinia Pharmaceuticals by 1.1% during the second quarter. Bank of New York Mellon Corp now owns 81,950 shares of the biotechnology company’s stock valued at $502,000 after purchasing an additional 931 shares during the last quarter. 28.17% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/06/aurinia-pharmaceuticals-auph-upgraded-by-zacks-investment-research-to-hold.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Get a free copy of the Zacks research report on Aurinia Pharmaceuticals (AUPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.